Cantor Fitzgerald Boosts Artiva Biotherapeutics (NASDAQ:ARTV) Price Target to $40.00

Artiva Biotherapeutics (NASDAQ:ARTV) had its price target hoisted by research analysts at Cantor Fitzgerald from $10.00 to $40.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 251.80% from the company’s current price.

A number of other research analysts have also weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, May 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Wedbush raised their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, HC Wainwright raised their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

Artiva Biotherapeutics Trading Up 4.4%

ARTV stock traded up $0.48 during midday trading on Monday, reaching $11.37. The stock had a trading volume of 199,153 shares, compared to its average volume of 281,670. The company’s fifty day simple moving average is $7.59 and its 200 day simple moving average is $5.35. The company has a market cap of $281.03 million, a price-to-earnings ratio of -3.23 and a beta of 2.86. Artiva Biotherapeutics has a 52-week low of $1.47 and a 52-week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Sell-side analysts predict that Artiva Biotherapeutics will post -3.33 EPS for the current year.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ARTV. Marshall Wace LLP purchased a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $79,000. Qube Research & Technologies Ltd purchased a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $58,000. Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $67,000. Bridgeway Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $53,000. Finally, BNP Paribas Financial Markets raised its holdings in Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares during the period.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.